M&A Deal Summary |
|
---|---|
Date | 2021-03-04 |
Target | ISC |
Sector | Insurance |
Buyer(s) | KKR |
Sellers(s) | Sightway Capital |
Deal Type | Secondary Buyout |
Advisor(s) | Morgan Stanley (Financial) Lowenstein Sandler (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Private Equity Firm |
---|---|
Founded | 1976 |
PE ASSETS | 510.0B USD |
Size | Mega |
Type | Sector Agnostic |
KKR is a global investment firm founded by Jerome Kohlberg, Henry Kravis, and George Roberts. The Firm is separated into several business segments including private markets, public markets, capital markets, and other principal activities. KKR's private equity practice invests in management buyouts, take privates, corporate divestitures, industry consolidations, and partnerships with family-owned companies. KKR will invest in a broad range of industries and companies and will consider businesses throughout North America, Europe, Asia, and Australia/New Zealand. Sectors of interest include chemicals, consumer products, energy and natural resources, financial services, healthcare, industrial, media/communications, retail, and technology. In addition to its traditional principal investment activity business, KKR also invests in infrastructure assets. KKR was formed in 1976 and is based in New York, New York.
DEAL STATS | # |
---|---|
Overall | 377 of 483 |
Sector (Insurance) | 10 of 13 |
Type (Secondary Buyout) | 75 of 107 |
State (New York) | 14 of 19 |
Country (United States) | 159 of 210 |
Year (2021) | 8 of 52 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-03-03 |
Nordic Bioscience
Herlev, Denmark Nordic Bioscience is an expert in the extracellular matrix (ECM) with experience in biomarker development, clinical and pre-clinical research. Fragments from the reactive stroma and ECM have been identified by the research team at Nordic Bioscience and corresponding quantification assays have been developed in parallel. Nordic Bioscience was founded in 1991 and is based in Herlev, Denmark. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-03-12 |
Cordis
Miami Lakes, Florida, United States Cordis is a provider of cardiovascular and endovascular medical devices. Founded in 1966, the Company has a long history of innovation in high-quality and minimally-invasive cardiovascular technology. Its products are primarily used in procedures to diagnose and treat the narrowing or blockage of arteries. Cordis was founded in 1966 and is based in Miami Lakes, Florida. |
Buy | $1.0B |
Sightway Capital is the private equity investment arm of hedge fund Two Sigma. Sightway Capital focuses on opportunities in the financial services sector as well as investing in real assets. Sightway Capital was established in 2017 and is based in New York City.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Insurance) | 1 of 1 |
Type (Secondary Buyout) | 1 of 1 |
State (New York) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2021) | 1 of 1 |